Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial

Miller, I. (Ian); Scheffer, I.E. (Ingrid E.); Gunning, B. (Boudewijn); Sanchez-Carpintero, R. (Rocío); Gil-Nagel, A. (Antonio); Perry, M.S. (M. Scott); Saneto, R.P. (Russell P.); Checketts, D. (Daniel); Dunayevich, E. (Eduardo); Knappertz, V. (Volker)

Issue Date:

2020

ISSN:

2168-6149

Note:

Citation:

Miller, I. (Ian); Scheffer, I.E. (Ingrid E.); Gunning, B. (Boudewijn); et al. "Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial". JAMA Neurology. 77 (5), 2020, 613 - 621

Abstract

Question Is adjunctive cannabidiol at doses of 10 and 20 mg/kg/d superior to placebo in reducing convulsive seizure frequency in patients with Dravet syndrome? Findings This double-blind clinical trial randomized 199 children with Dravet syndrome to cannabidiol (10 or 20 mg/kg/d) or matched placebo for 14 weeks. Convulsive seizure frequency compared with baseline was reduced by 48.7% in the 10-mg/kg/d cannabidiol group and 45.7% in the 20-mg/kg/d cannabidiol group vs 26.9% in the placebo group. Meaning Both doses of adjunctive cannabidiol were similarly efficacious in reducing convulsive seizures associated with Dravet syndrome.

URI:

https://hdl.handle.net/10171/66183

DOI:

10.1001/jamaneurol.2020.0073

Appears in Collections:

DA - CUN - Pediatría - Artículos de revista

Files in This Item: